Physician profile
Thomas Green
NPI 1487655320
$6,971.83
in general payments reported to CMS, 2019-2025
42 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $926 · 2021: $920 · 2022: $984 · 2023: $1,285 · 2024: $1,294 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,596 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,596.37 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,087.04 | 2021-2025 | |
| Novo Nordisk INC | $784.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $682.62 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $561.38 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $512.17 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $414.67 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.74 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $310.56 | 2019-2022 | |
| Abbott Laboratories | $272.79 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $237.15 | 2019-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $224.06 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $160.49 | 2022-2025 | |
| Exact Sciences Corporation | $107.92 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $91.80 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $87.95 | 2021-2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.